Pulmonary & Sleep Consultants

Personal and Professional Pulmonary & Sleep services in South Florida

  • Home
  • Services
    • Pulmonary Medicine
    • Obstructive Sleep Apnea (OSA)
    • Lung nodules
    • Weight Management
  • Our Team
    • J.J. Rajter MD
    • Juliana Cepelowicz Rajter, MD
  • Contact Us
  • Resources
    • Do you have OSA?
    • Instructions
    • Discount Coupons and Links
    • Medication Information
    • Post a review
    • Hospital Affiliations – Fort Lauderdale & South Florida
  • Blog
  • Store
    • CPAP Masks
    • CPAP Supplies
    • Pulmonary Supplies
    • Over The Counter Medications
    • Smoking Cessation
  • Patient Portal

Zepbound (tirzepatide) for treatment of Obstructive Sleep Apnea

Dual Agonist Therapy for Chronic Weight Management

Zepbound is a once-weekly injectable prescription medicine. It is a dual agonist, mimicking two hormones (GLP-1 and GIP) to regulate appetite and improve how your body processes sugar and fat.


1. What is Zepbound?

  • Indication: For adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related medical conditions (e.g., high blood pressure, Type 2 diabetes, or sleep apnea).
  • Usage: Must be used in combination with a reduced-calorie diet and increased physical activity.

2. Expected Weight Loss Results

In clinical trials (SURMOUNT studies), Zepbound showed significant weight loss results over 72 weeks:

Dose Level Avg. Weight Loss (%) Avg. Weight Loss (lbs)*
High Dose (15 mg) 20.9% ~48 lbs
Medium Dose (10 mg) 19.5% ~44 lbs
Low Dose (5 mg) 15.0% ~34 lbs
Placebo 3.1% ~7 lbs

*Based on an average starting weight of ~230 lbs.

The 25% Goal: Approximately 1 in 3 people taking the 15 mg dose lost 25% or more of their total body weight.

3. How to Use the Injection

  • Schedule: Inject once weekly on the same day each week, at any time of day.
  • Administration: Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate sites weekly.
  • Meals: Can be taken with or without food.
  • Storage: Store pens in the refrigerator. Pens can stay at room temperature for up to 21 days if necessary.

4. Dosage Schedule

Your doctor will use a step-up approach to help your body adjust:

  • Month 1: 2.5 mg weekly (Starting dose; not for weight loss).
  • Month 2: 5 mg weekly.
  • Increases: Dose may increase by 2.5 mg every 4 weeks until reaching your maintenance dose (up to 15 mg).

5. Common Side Effects

  • Nausea and vomiting
  • Diarrhea or constipation
  • Stomach pain or indigestion
  • Fatigue and temporary hair loss

6. Important Safety Considerations

Boxed Warning: Thyroid Tumors Zepbound caused thyroid tumors in animal studies. It is unknown if it causes these in humans.
  • Do not use if you or a family member have ever had Medullary Thyroid Carcinoma (MTC) or MEN 2.
  • Report any neck lumps, trouble swallowing, or hoarseness immediately.

Other Serious Warnings:

  • Severe Gastrointestinal Disease: Zepbound is not recommended for people with severe gastroparesis (stomach paralysis).
  • Birth Control Warning: Zepbound may make oral birth control pills less effective. If you use the pill, talk to your doctor about switching to a non-oral method or adding a barrier method (like condoms) for 4 weeks after starting and after each dose increase.
  • Pancreatitis: Seek help for severe abdominal pain that doesn’t go away.
  • Kidney Issues: Severe dehydration from vomiting can lead to kidney damage.

7. Zepbound vs. Wegovy

Mechanism: Wegovy mimics one hormone (GLP-1); Zepbound mimics two (GLP-1 & GIP).

Efficacy: In trials, Zepbound generally led to higher average weight loss (20.2% vs 13.7% for Wegovy).


8. Manufacturer Coupons

We want to ensure your prescribed treatment is as affordable as possible. Many pharmaceutical manufacturers offer Copay Savings Cards that can significantly reduce your out-of-pocket costs.

While our office assists in identifying potential savings, manufacturer discount programs are third-party entities. Pulmonary and Sleep Consultants does not administer these programs and cannot guarantee eligibility or the final cost of your medication. Programs are subject to change or cancellation by the manufacturer without notice.

This information is for educational purposes and does not replace professional medical advice. Always consult your healthcare provider.

Recent Posts

  • Dr. Rajter’s opening statement to US Senate Homeland Security Hearing on early treatment for COVID-19.
  • Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)
  • Chest Journal. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019
  • Chest Journal Club Webinar. Icon Study: Use of Ivermectin in Hospitalized Patients With COVID-19.

Contact Info

Pulmonary and Sleep Consultants
1001 S. Andrews Ave
Suite 100
Fort Lauderdale, FL 33316

Tel. 954-906-6000
Fax. 954-860-7650

Copyright © 2026 Pulmonary and Sleep Consultants     ·     Built by MySalesButler.com, LLC